金达威｜调研要点：多特倍斯26年加大投入，看好代工厂VB改善趋势（20260127） 1辅酶Q10：目前价格处于合理区间（不会引发过多竞争），12月辅酶Q10价格有所下降，1-2月价格回升需求旺 盛，预计26年量升价减，希望毛利长期保持45%-50%。 2‼代工厂VB：#预计后续收入加速。 目前只有片剂和硬胶囊，预计4月开始软胶囊产线。 #VB目前工艺 金达威｜调研要点：多特倍斯26年加大投入，看好代工厂VB改善趋势（20260127） 1辅酶Q10：目前价格处于合理区间（不会引发过多竞争），12月辅酶Q10价格有所下降，1-2月价格回升需求旺 盛，预计26年量升价减，希望毛利长期保持45%-50%。 2‼代工厂VB：#预计后续收入加速。 目前只有片剂和硬胶囊，预计4月开始软胶囊产线。 ①抖音在做跨境产品管控，公司优势突出； ②美国代工厂加大投入，全产业链能力优势突出（即便下游利润较薄，但是原料代工有优势）。 4变更募集资金用途： ①智慧工厂：后续会做自己品牌的保健品，可能用国内已有品牌金乐心，聚焦物美价廉和二三线城市，不做全品 类而是聚焦有原料的产品（例如辅酶Q10、PQQ等）。 #VB目前工艺、交付期已经 ...

Core Viewpoint - The report from Tianfeng Securities highlights that Jindawei's main business includes health products, coenzyme Q10, and vitamin series, with a projected revenue of 1.728 billion yuan in H1 2025, representing a year-on-year increase of 13.5%, and a net profit attributable to the parent company of 247 million yuan, reflecting a significant year-on-year growth of 90.1% [1] Group 1: Company Performance - The health product market is continuously expanding, driven by increasing health consumption demand [1] - In the short term, the company expects stable growth in coenzyme Q10 and a surge in domestic demand for its health product brand, Duote Beisi, indicating a continuation of high growth in H1 2025 [1] - For the medium to long term, the company has a clear growth path, leveraging its synthetic biology technology platform to incubate high-value new products like EPA, potentially replicating the success of coenzyme Q10 [1] Group 2: Investment and Growth Projections - The company plans to use funds from convertible bonds for the expansion and renovation of coenzyme Q10 production, as well as projects for 30,000 tons of allulose and 5,000 tons of inositol, which are expected to provide new growth points for performance [1] - The brandization of the company's health products is also undergoing continuous upgrades and implementation [1] - Projected net profits attributable to the parent company for 2025-2027 are estimated at 440 million, 650 million, and 790 million yuan, with growth rates of 29%, 47%, and 22% respectively [1] Group 3: Valuation and Market Position - The company is compared to peers such as Tongrentang and Ruoyuchen, with a PEG ratio of 1.1 for 2026, corresponding to a PE of 35X [1] - The target market value is set at 15.7 billion yuan, with a target price of 25.7 yuan, maintaining a "buy" rating [1]